Survodutide development — anyone tracking the BI program?

Boehringer-Zealand's GLP-1/glucagon dual agonist. Mechanistically similar to mazdutide but different molecule. Their MASH trial readouts have been interesting — substantial liver fat reductions.

Feels like the dual GLP-1/glucagon class is getting crowded fast. Reta is winning the obesity race because of triple agonism but for MASH specifically the dual approaches might have advantages.